Global Ammonia-13 Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

According to our (Global Info Research) latest study, the global Ammonia-13 market size was valued at US$ 133 million in 2025 and is forecast to a readjusted size of US$ 288 million by 2032 with a CAGR of 11.8% during review period.
In 2025, global Ammonia-13 production was approximately 18,000 grams, with a global average market price of around $7,200 per gram. That year, total global production capacity for Ammonia-13 reached approximately 25,000 grams, and the industry's average gross profit margin stood at about 45%. Nitrogen-13 (^13N) is an artificial radioactive isotope with an atomic number of 7 and a mass number of 13. It is a proton-rich radionuclide mainly produced by cyclotrons through the nuclear reaction of oxygen-16 targets with protons (^16O(p,α)^13N). Nitrogen-13 has a short half-life of approximately 9.97 minutes and decays by positron emission (β⁺ decay) into stable carbon-13 (^13C), producing 511 keV annihilation photons. Due to these characteristics, ^13N is widely used in positron emission tomography (PET). The most important clinical form is nitrogen-13 ammonia (^13N-Ammonia, ^13N-NH₃), which provides excellent myocardial uptake and blood-flow tracing capability and is considered a key PET radiopharmaceutical for myocardial perfusion imaging.
The upstream sector of the nitrogen-13 industry includes cyclotron equipment suppliers, oxygen-16 enriched water target suppliers, radiochemical synthesis systems, and quality-control equipment providers. Due to the extremely short half-life of nitrogen-13 (approximately 10 minutes), long-distance transportation is impractical. Therefore, ^13N production generally follows an on-site manufacturing model using medical cyclotrons located in hospitals, nuclear medicine centers, or radiopharmaceutical production facilities. Key upstream technologies include proton beam control, target system engineering, automated synthesis modules, and radiochemical quality management, requiring high equipment reliability and process precision. The midstream sector focuses on the production, quality control, and clinical supply of nitrogen-13 ammonia (^13N-Ammonia) radiopharmaceuticals. After nitrogen-13 is generated by cyclotrons, it undergoes radiochemical synthesis to produce injectable ^13N-NH₃, followed by sterile filtration, radioactive activity measurement, chemical purity testing, and pharmaceutical validation. Due to its very short half-life, ^13N-Ammonia is typically produced on-site by hospitals or supplied through regional radiopharmaceutical centers rather than through conventional distribution networks. Major participants include nuclear medicine departments, PET imaging centers, hospital radiopharmacy units, and specialized radiopharmaceutical organizations. The downstream applications of nitrogen-13 are primarily concentrated in nuclear medicine diagnostics and biomedical research, with myocardial perfusion PET imaging being the most important application. ^13N-Ammonia enables quantitative evaluation of myocardial blood flow, supporting coronary artery disease diagnosis, myocardial flow reserve assessment, and cardiovascular risk evaluation. In addition, nitrogen-13 is used in brain function studies, metabolic research, and tracer-based biomedical experiments. With the expansion of PET/CT and PET/MRI systems, the growth of precision medicine, and increasing demand for cardiovascular diagnostics, nitrogen-13 ammonia continues to play an important role as a high-performance short-lived PET tracer.
The increasing global burden of cardiovascular diseases is driving demand for myocardial perfusion imaging and precision cardiovascular diagnostics. Nitrogen-13 ammonia (^13N-NH₃) offers advantages including high myocardial uptake, excellent image quality, and quantitative assessment of myocardial blood flow, making it one of the important PET tracers for cardiac imaging. With the growing need for early coronary artery disease detection, myocardial flow reserve evaluation, and personalized treatment, more medical institutions are adopting PET/CT and PET/MRI technologies, further enhancing the clinical value of ^13N-Ammonia.
Advancements in PET/CT and PET/MRI technologies are creating broader application opportunities for short-lived radioactive tracers. Due to its short half-life, ^13N-Ammonia can reduce patient radiation exposure while enabling rapid imaging and dynamic blood-flow assessment, aligning with the development of precision medicine. In the future, improvements in high-resolution PET systems, artificial intelligence-assisted image analysis, and quantitative PET technologies will further enhance the role of ^13N-Ammonia in cardiovascular risk prediction, treatment evaluation, and clinical research.
Because ^13N-Ammonia has an extremely short half-life of approximately 10 minutes, it cannot be distributed through conventional logistics networks. Its market development therefore relies heavily on medical cyclotron infrastructure and on-site radiopharmaceutical production capabilities. In recent years, hospitals, nuclear medicine centers, and PET imaging facilities worldwide have expanded cyclotron installations, improving local ^13N-Ammonia production capacity. Meanwhile, advances in automated radiochemical synthesis systems and quality-control technologies are enhancing production efficiency, safety, and standardization, contributing to a more mature supply ecosystem.
Report Scope
This report is a detailed and comprehensive analysis for global Ammonia-13 market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Ammonia-13 market size and forecasts, in consumption value ($ Million), sales quantity (Gram), and average selling prices (US$/g), 2021-2032
Global Ammonia-13 market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Gram), and average selling prices (US$/g), 2021-2032
Global Ammonia-13 market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Gram), and average selling prices (US$/g), 2021-2032
Global Ammonia-13 market shares of main players, shipments in revenue ($ Million), sales quantity (Gram), and ASP (US$/g), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Ammonia-13
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Ammonia-13 market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Ionetix, SOFIE, Spectron MRC LLC, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Ammonia-13 market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
High Specific Activity
Low Specific Activity
Market segment by Preparation Method
Cyclotron
Automated Synthesis Module
Research and Experimental
Market segment by Product Form
Ammonia N-13 Injection
Ammonia N-13-labeled Tracer Preparation
Market segment by Production and Supply Model
Hospital-produced Ammonia-13
Commercially supplied Ammonia-13
Market segment by Application
Medical Imaging
Scientific Research
Major players covered
Ionetix
SOFIE
Spectron MRC LLC
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter Outline
Chapter 1, to describe Ammonia-13 product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Ammonia-13, with price, sales quantity, revenue, and global market share of Ammonia-13 from 2021 to 2026.
Chapter 3, the Ammonia-13 competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Ammonia-13 breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Ammonia-13 market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Ammonia-13.
Chapter 14 and 15, to describe Ammonia-13 sales channel, distributors, customers, research findings and conclusion.